Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 2/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.34 |
| ▸ | HTR1A | P08908 | 5/20 | 0.33 |
| ▸ | AIMP2 | Q13155 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5767727 | 0.87 | CA2 (0.36) | CA2CYP1A2LMNASMN1; SMN2NPC1 | |
| SCHEMBL7240006 | 0.86 | CA2 (0.35) | CA2HTR1A | |
| SCHEMBL7236260 | 0.86 | CA2 (0.35) | CA2HTR1A | |
| SCHEMBL6109572 | 0.86 | HTR1A (0.46) | CA2HTR1ASLC6A4LMNAKDM4E | |
| SCHEMBL6630732 | 0.86 | HTR1A (0.46) | CA2HTR1ASLC6A4LMNAKDM4E | |
| SCHEMBL6631639 | 0.85 | KDM4E (0.37) | CA2CYP1A2EPHX2LMNAKDM4E | |
| SCHEMBL6630585 | 0.84 | HTR1A (0.39) | CA2HTR1AAIMP2SLC6A4KDM4E | |
| SCHEMBL6631842 | 0.84 | KMT2A (0.38) | EPHX2LMNAKDM4EL3MBTL1HTT | |
| SCHEMBL6630209 | 0.84 | HTR1A (0.37) | CA2HTR1AAIMP2SLC6A4KDM4E | |
| SCHEMBL4821516 | 0.82 | CA2 (0.38) | CA2HTR1AAIMP2LMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090042874-A1 | ANTIDEPRESSANT HETEROARYL DERIVATIVES OF HETEROCYCLE-FUSED BENZODIOXANS | WYETH (US) | 2009-02-12 | — | — | US | disclosed |
| WO-2008150848-A1 | ANTIDEPRESSANT HETEROARYL DERIVATIVES OF HETEROCYCLE-FUSED BENZODIOXANS | WYETH (US) | 2008-12-11 | — | — | WO | disclosed |
| US-20070004702-A1 | Antidepressant azaheterocyclylmethyl derivatives of heterocycle-fused benzodioxans | WYETH (US) | 2007-01-04 | — | — | US | disclosed |
| US-20060293301-A1 | Antidepressant azaheterocyclylmethyl derivatives of heterocycle-fused benzodioxans | WYETH (US) | 2006-12-28 | — | — | US | disclosed |
| US-7153849-B2 | Antidepressant arylpiperazine derivatives of hetrocycle-fused benzodioxans | WYETH (US) | 2006-12-26 | — | — | US | disclosed |
| US-20060276481-A1 | Antidepressant arylpiperazine derivatives of heterocycle-fused benzodioxans | WYETH (US) | 2006-12-07 | — | — | US | disclosed |
| EP-1546151-B1 | ANTIDEPRESSANT CYCLOALKYLAMINE DERIVATIVES OF HETEROCYCLE-FUSED BENZODIOXANS | WYETH CORP (US) | 2006-04-12 | — | — | EP | disclosed |
| EP-1546151-A1 | ANTIDEPRESSANT CYCLOALKYLAMINE DERIVATIVES OF HETEROCYCLE-FUSED BENZODIOXANS | Wyeth (US) | 2005-06-29 | — | — | EP | disclosed |
| US-6911445-B2 | For reatment of depression, childhood depression, dysthymia, anxiety, panic disorder, post-traumatic stress disorder, premenstrual dysphoric disorder, attention deficit disorder, obsessive-compulsive disorder, cocaine and alcohol addiction | WYETH (US) | 2005-06-28 | — | — | US | disclosed |
| EP-1537121-A1 | ANTIDEPRESSANT ARYLPIPERAZINE DERIVATIVES OF HETEROCYCLE-FUSED BENZODIOXANS | Wyeth (US) | 2005-06-08 | — | — | EP | disclosed |
| US-20040171667-A1 | Antidepressant cycloalkylamine derivatives of heterocycle-fused benzodioxans | WYETH | 2004-09-02 | — | — | US | disclosed |
| US-20040142926-A1 | Antidepressant arylpiperazine derivatives of heterocycle-fused benzodioxans | WYETH | 2004-07-22 | — | — | US | disclosed |
| WO-2004024732-A1 | ANTIDEPRESSANT CYCLOALKYLAMINE DERIVATIVES OF HETEROCYCLE-FUSED BENZODIOXANS | WYETH (US) | 2004-03-25 | — | — | WO | disclosed |
| WO-2004024731-A1 | ANTIDEPRESSANT ARYLPIPERAZINE DERIVATIVES OF HETEROCYCLE-FUSED BENZODIOXANS | WYETH (US) | 2004-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293301-A1 | Antidepressant azaheterocyclylmethyl derivatives of heterocycle-fused benzodioxans | CRH, HTR5A, DBH | NR3C1 21/4885CA2 4770/4885CYP1A2 73/4885 |
| US-20060276481-A1 | Antidepressant arylpiperazine derivatives of heterocycle-fused benzodioxans | HTR5A, CRH, TAAR5 | NR3C1 58/4885CA2 4812/4885CYP1A2 50/4885 |
| US-20040142926-A1 | Antidepressant arylpiperazine derivatives of heterocycle-fused benzodioxans | HTR5A, CYP19A1, CRH | NR3C1 59/4885CA2 4798/4885CYP1A2 40/4885 |
| US-20040171667-A1 | Antidepressant cycloalkylamine derivatives of heterocycle-fused benzodioxans | HTR5A, CRH, TPH1 | NR3C1 89/4885CA2 4814/4885CYP1A2 151/4885 |
| US-20090042874-A1 | ANTIDEPRESSANT HETEROARYL DERIVATIVES OF HETEROCYCLE-FUSED BENZODIOXANS | HTR5A, CRH, CYP17A1 | NR3C1 58/4885CA2 4795/4885CYP1A2 61/4885 |
| US-20070004702-A1 | Antidepressant azaheterocyclylmethyl derivatives of heterocycle-fused benzodioxans | CRH, CYP19A1, HTR5A | NR3C1 18/4885CA2 4830/4885CYP1A2 71/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.